/ Physicians

Drug Shortage and Recall: Update Ranitidine injectable


As previously communicated, all oral ranitidine products in Canada have been recalled due to the presence of an impurity, NDMA. Ranitidine 25 mg/mL X 2 mL injectable was initially exempt from recall procedures but Health Canada has now placed a stop distribution on existing supply in order to conduct further quality assurance testing. NH has approximately 3 weeks supply of injectable ranitidine in pharmacies in addition to approximately 2 weeks supply on wards; however, some wardstock may be expiring shortly as well. NH may stock out before more product is available.

Further information and practice implications.